Literature DB >> 24425061

Update in therapeutic approaches to plaque stabilization.

Stephen J Nicholls1, Yu Kataoka.   

Abstract

Increasing pathological insights have highlighted the role of plaque instability in the pathogenesis of acute ischemic syndromes. These studies have identified a specific plaque phenotype, characterized by large burden, expansive arterial wall remodeling, and greater composition of lipid, inflammatory, and necrotic material, as the disease most likely to rupture and provoke acute ischemia. Accordingly, considerable efforts have been made to develop more effective strategies to identify patients more likely to harbor such lesions and to passivate this disease from both a prophylactic and a therapeutic perspective. The approaches to management of plaque stabilization are reviewed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24425061     DOI: 10.1007/s11883-013-0392-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  94 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 3.  Bioabsorbable coronary stents.

Authors:  John A Ormiston; Patrick W S Serruys
Journal:  Circ Cardiovasc Interv       Date:  2009-06       Impact factor: 6.546

4.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

5.  Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

Authors:  Stephen J Nicholls; H Bryan Brewer; John J P Kastelein; Kathryn A Krueger; Ming-Dauh Wang; Mingyuan Shao; Bo Hu; Ellen McErlean; Steven E Nissen
Journal:  JAMA       Date:  2011-11-16       Impact factor: 56.272

6.  Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

Authors:  James M McKenney; Michael J Koren; Dean J Kereiakes; Corinne Hanotin; Anne-Catherine Ferrand; Evan A Stein
Journal:  J Am Coll Cardiol       Date:  2012-03-28       Impact factor: 24.094

7.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

8.  Angiotensin II-inducible smooth muscle cell apoptosis involves the angiotensin II type 2 receptor, GATA-6 activation, and FasL-Fas engagement.

Authors:  Nicole Y Tan; Jian-Mei Li; Roland Stocker; Levon M Khachigian
Journal:  Circ Res       Date:  2009-07-23       Impact factor: 17.367

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

Review 10.  The LDL modification hypothesis of atherogenesis: an update.

Authors:  Daniel Steinberg
Journal:  J Lipid Res       Date:  2008-11-15       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.